It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Renal fibrosis is controlled by profibrotic and antifibrotic forces. Exploring anti-fibrosis factors and mechanisms is an attractive strategy to prevent organ failure. Here we identified the JNK-associated leucine zipper protein (JLP) as a potential endogenous antifibrotic factor. JLP, predominantly expressed in renal tubular epithelial cells (TECs) in normal human or mouse kidneys, was downregulated in fibrotic kidneys. Jlp deficiency resulted in more severe renal fibrosis in unilateral ureteral obstruction (UUO) mice, while renal fibrosis resistance was observed in TECs-specific transgenic Jlp mice. JLP executes its protective role in renal fibrosis via negatively regulating TGF-β1 expression and autophagy, and the profibrotic effects of ECM production, epithelial-to-mesenchymal transition (EMT), apoptosis and cell cycle arrest in TECs. We further found that TGF-β1 and FGF-2 could negatively regulate the expression of JLP. Our study suggests that JLP plays a central role in renal fibrosis via its negative crosstalk with the profibrotic factor, TGF-β1.
Qi Yan et al. find that JNK-associated leucine zipper protein (Jlp) counteracts the profibrotic effects of TGF-β1 and autophagy on renal tubular epithelial cells and that TGF-β1 and FGF-2 can negatively regulate the expression of Jlp. These findings provide insights into the role of Jlp in kidney fibrosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Renmin Hospital of Wuhan University, Department of Nephrology, Wuhan, China (GRID:grid.412632.0) (ISNI:0000 0004 1758 2270); Huazhong University of Science and Technology, Department of Geriatrics, Tongji Hospital, Tongji Medical College, Wuhan, China (GRID:grid.33199.31) (ISNI:0000 0004 0368 7223)
2 Renmin Hospital of Wuhan University, Department of Nephrology, Wuhan, China (GRID:grid.412632.0) (ISNI:0000 0004 1758 2270)
3 Renmin Hospital of Wuhan University, Department of Nephrology, Wuhan, China (GRID:grid.412632.0) (ISNI:0000 0004 1758 2270); Mayo Clinic, Department of Internal Medicine, and Biochemistry and Molecular Biology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
4 Cancer Research Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan (GRID:grid.9707.9) (ISNI:0000 0001 2308 3329)
5 General Hospital of Central Theater Command, Department of Medical Laboratory Center, Wuhan, China (GRID:grid.9707.9)
6 Mayo Clinic, Department of Internal Medicine, and Biochemistry and Molecular Biology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)